Methods of treating hypertension

Details Methods of treating hypertension Methods of treating hypertension

2005-08-24

2010-10-26

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07820667

ABSTRACT:
It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS.The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I):wherein R1and R2each represents a hydrogen atom or, taken together with each other, represent a single bond, while R3represents —CH(OH)CH(OH)CH3, —CH(OCOCH3)CH(OCOCH3)CH3, —CH3, —CH2OH, or a phenyl group when R1and R2each represents a hydrogen atom, or —COCH(OH)CH3when R1and R2together represent a single bond, or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 5196533 (1993-03-01), Ayling et al.
patent: 6288067 (2001-09-01), Okamura et al.
patent: 0722731 (1996-07-01), None
patent: 59-25323 (1984-02-01), None
patent: 59-76086 (1984-04-01), None
patent: 61-277618 (1986-12-01), None
patent: 63-267781 (1988-11-01), None
patent: 7188024 (1995-07-01), None
patent: 07188233 (1995-07-01), None
patent: WO 95/32203 (1995-05-01), None
patent: WO98/08516 (1998-03-01), None
Cosentio et al., Circulation, 91(1), (1995), 139-144.
West et al., Journal of Endocrinology, (135, Suppl., p. 62, 1992) (abstract).
Kukor et al., Placenta, (Jan. 1996), 17(1), pp. 69-73.
Shintaku et al., Chemistry and Biology of Pteridines and Folates (Jun. 1997), Proceedings of the International Symposium of Pteridines and Folates, pp. 765-769.
Ishihara et al., Archives of Biochemistry and Biophysics, 298(2), pp. 726-730 (abstract), 1992.
Sheng et al., J. Neurochem., 61(3), 1120-6 (abstract), 1993.
Van Amsterdam J.G. and Werner, J. “Tetrahydrobiopterin induces . . . cGMP level” 1992 Eur. J. Pharmacol. vol. 215, pp. 349-350 (abstract).
Fukushima et al., “Analysis of Reduced Forms of Biopterin In Biological Tissues and Fluids”, Analytical Biochemistry, 102, 1980, pp. 176-188.
Ujiie et al., “Localization and Regulation of Endothelial NO Synthase mRNA Expression in Rat Kidney”, American J. Physiol., 267, 1994, pp. F296-F302.
Hirata et al., “Direct Measurements of Endothelium-Derived Nitric Oxide Release by Stimilation of Endothelin Receptors in Rat Kidney and Its Alteration in Salt-Induced Hypertension”, Circulation, vol. 91, No. 4, 1995, pp. 1229-1235.
Hayakawa et al., “Long-term Administration of L-Arginine Improves Nitric Oxide Release From Kidney in Deoxycorticosterone Acetate-Salt Hypertensive Rats”, Hypertension. vol. 23, No. 6, Part 1, 1994, pp. 752-756.
Rector et al., “Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients With Heart Failure”, Circulation, vol. 93, No. 12, 1996, pp. 2135-2141.
Egashira et al., “Effects of L-Arginine Supplementation on Endothelium-Dependent Coronary Vasodilation in Patients With Angina Pectoris and Normal Coronary Arteriograms”, Circulation, vol. 94, No. 2, 1996, pp. 130-134.
Ishihara et al. Archives of Biochemisty and Biophysics, 298(2), pp. 726-730 (abstract).
Sheng et al., J. Neurochem., 61(3), 1120-6 (abstract).
Biochemical and Biophysical Research Communications, vol. 215, No. 3, pp. 1119-1129, (1995); Pei-Feng Chen et al. “Cysteine 99 of Endothelial Nitric Oxide Synthase (Nos-III) is Critical For Tetrahydrobiopterin-Dependent Nos-III Stability and Activity”.
Journal of Cardiovascular Pharmacology, vol. 26, No. 6, pp. 916-922 (1995); Voker Vallon et al. “Interactive Control of Renal Function by a2-Adrenergic System and Nitric Oxide: Role of Angiotensin II”.
Science, vol. 272, No. 5262, pp. 689-693, (1996) Gary H. et al. “Molecular Therapies for Vascular Diseases”.
Laboratory Investigation, vol. 72, No. 1, pp. 17-24 (1995) Ichiei Narita et al. “Nitric Oxide Mediates Immunologic Injury to Kidney Mesangium In Experimental Glomerulonephritis.”
Ann. Med., vol. 27, No. 3, pp. 353-7, (1995) Tikkanen, Iikka et al. “Nitric Oxide in Hypertension and Renal Diseases”.
Baker et al. “Plasma From Women With Preeclampsia Increases Endothelial Cell Nitric Oxide Production” Hypertension. 1995, 26, pp. 244-248.
Davidge et al. “NOS expression is increased in endothelial cells exposed to plasma from women with preeclampsia” J. Physiol. Sep. 1995, 268(3 Pt 1):H1 106-12.
Silver et al. “Evaluation of nitric oxide as a mediator of severe preeclampsia” Am. J. Obste. Gynecol. Oct. 1996, 175(4 Pt 1):1013-7.
Scott-Burden, T., “Regulation of Nitric Oxide Production by Tetrahydrobiopterin”, Circulation, vol. 91, 1995, pp. 248-250.
Yamamoto et al, “A Comparison of Seplapterin and Tetrahydrobiopterin Uptake by BRL2H3 Cells,” Pteridlnes, vol. 7, 1996, 154-156.
Yaoka et al, “Antihypertensive activity of the angiotensin . . . in various hypertensive animal models,” Nippon Yakugaku Zasshi, 1993, 102(1): 35-45 (PubMed abstract only).
Yamamoto et al, “Pharmacological profile of valsartin, . . . effects of valsartan in hypertensive models,” Arznelittelforschung, 1997, 47(5): 604-612 (PubMed abstract only).
Nava et al, “Alterations to the nitric oxide pathway in the spontaneously hypertensive rat,” J Hypertension, 1998, 16(5): 609-615.
Kulper et al, “Decreased cerebrospinal fluid nitrate levels in Parkinson's Disease, . . . and multiple system atrophy patients,” Journal of the Neurological Sciences, 121(1994) 46-49.
Brand et al, “Tetrahydrobiopterin deficiency and brain nitric oxide synthase I the hph1 mouse,” J Inherit Metab Dis, 1995, 18(1), 33-39.
Meininger et al., impaired nitric oxide production . . . due to tetrahydrobiopterin deficiency, Biochem J. (2000) 349, 353-356.
Fortepiani and Reckelhoff, “Treatment with tetrahydrobiopterin . . . testosterone synthesis,”Amer. J. Physiol. Regul. Integr. Comp. Physiol. 288:733-736 (2005) (first published Dec. 2004).
Vasques-Vivar et al., “The ratio between tetrahydrobioprterin . . . spin trapping study,” Biochem. J. 362: 733-739 (2002).
Channon, K., “Tetrahydrobiopterin, Regulator of Endothelial . . . Vascular Disease,” Trends Cardiovasc. Med 14:323-327 (2004).
Kinoshita et al., “Exogenous tetrahydrobiopterin . . . canine basilar artery,” Am J Physiol. (Aug. 1996); 271(2 Pt 2): H738-43.
Rosenkranz-Weiss et al., “Regulation of Nitric Oxide . . . Umbilical Vein Endothelial Cells,” J. Clin. Invert. 93:2236-2243 (1994).
Van Amsterdam et al., “Tetrahydrobiopterin induces vasodilatation via enhancement of cGMP level,” Eur. J. Pharmacol. 215:349-350 (1992).
Lefever et al. 2003 Scientific Sessions of the American Heart Association, Nov. 9-12, 2003, Orlando, Florida, USA: Clinical Pathophysiology of Hypertension, Presentation No. AOP.43.3: 2378,[Published in Circulation, Oct. 28, 2003; 108(17 Suppl):IV1-7870].
Porkert et at., American College of Cardiology ACC.06, Atlanta, Georgia, Mar. 14, Poster Session, Session No. 1027, Presentation No. 1027-194(2006).
BioMarin Pharmaceutical Inc. (Novato, California, Feb. 20, 2007). BioMarin Announces Results from Phase 2 Clinical Study of 6R-BH4 in Poorly Controlled Hypertension. Press Release.
Pinto et al., “Lessons from rat models of hypertension: from Goldblatt to genetic engineering” Cardiovasc Res. Jul. 1988;39(1):77-88.
Mellouk, Sylvie et al. “Nitric Oxide-Mediated Antiplasmodial Activity in Human . . . Exogenous Tetrahydrobiopterin” Infection and Immunity, Sep. 1994, pp. 4043-4046.
Klatt, Peter, et al. “The Pteridine Binding Site of Brain Nitric Oxide Synthase” J. of Biological Chemistry, vol. 269, No. 19, May 13, 1994, pp. 13861-13866.
Kerwin, James et al., “Nitric Oxide: A New Paradigm for Second Messengers” J. Of Medicinal Chemistry, vol. 38, No. 22, Oct. 27, 1995, pp. 4343-4362.
Martasek et al. “Characterization of Bovine Endothelial Nitric Ox

Affiliated with

Also associated with

Rating

Methods of treating hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating hypertension will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176248